Research programme: antioxidant therapeutics - OXIS International

Drug Profile

Research programme: antioxidant therapeutics - OXIS International

Latest Information Update: 12 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OXIS Therapeutics
  • Class
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Neurological disorders; Parkinson's disease

Most Recent Events

  • 07 Apr 2006 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 07 Apr 2006 No development reported - Preclinical for Neurological disorders in USA (unspecified route)
  • 26 Mar 2004 OXIS International has been acquired by Axonyx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top